Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19463977 | 0.87 | KDM4E (0.54) | MAPTALDH1A1KDM4ETSHRHPGD | |
| SCHEMBL19493121 | 0.83 | KDM4E (0.43) | MAPTALDH1A1KDM4ETSHRHPGD | |
| SCHEMBL22280905 | 0.79 | BRD4 (0.37) | MAPTNR3C1PTPN11 | |
| SCHEMBL19492771 | 0.79 | MEN1 (0.47) | ALDH1A1HPGDMEN1KMT2ACNR2 | |
| SCHEMBL28634209 | 0.73 | HPGD (0.43) | MAPTALDH1A1KDM4ETSHRHPGD | |
| SCHEMBL28618587 | 0.70 | MAPT (0.40) | MAPTALDH1A1KDM4ETSHRHPGD | |
| SCHEMBL19492873 | 0.70 | KDM4E (0.50) | MAPTALDH1A1KDM4ETSHRHPGD | |
| SCHEMBL15466340 | 0.69 | KDM4E (0.50) | MAPTALDH1A1KDM4EHPGDNPC1 | |
| SCHEMBL22281228 | 0.68 | BRD4 (0.39) | MAPTNR3C1THRB | |
| SCHEMBL19464235 | 0.67 | MAPT (0.41) | MAPTALDH1A1KDM4ETSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442974-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| CN-109071545-B | Novel pyrazolopyrimidine derivatives | 拜耳动物保健有限责任公司 | 2021-08-03 | — | — | CN | disclosed |
| US-11001590-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| US-11001590-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| US-10934301-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-03-02 | — | — | US | disclosed |
| US-10934301-B2 | Pyrazolopyrimidine derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2021-03-02 | — | — | US | disclosed |
| US-20200299299-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-20200299299-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| US-20200239482-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-07-30 | — | — | US | disclosed |
| US-20200239482-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-07-30 | — | — | US | disclosed |
| US-10604525-B2 | Pyrazolopyrimidine derivatives | BAYAL ANIMAL HEALTH GMBH (DE) | 2020-03-31 | — | — | US | disclosed |
| US-20190071447-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604525-B2 | Pyrazolopyrimidine derivatives | P2RX5, RECQL, P2RX1 | MAPT 4497/4885ALDH1A1 1297/4885KDM4E 1438/4885 |
| US-11001590-B2 | Pyrazolopyrimidine derivatives | P2RX5, RECQL, P2RX1 | MAPT 4495/4885ALDH1A1 1228/4885KDM4E 1445/4885 |
| US-20190071447-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | MAPT 4497/4885ALDH1A1 1297/4885KDM4E 1438/4885 |
| US-20200239482-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | MAPT 4495/4885ALDH1A1 1228/4885KDM4E 1445/4885 |
| US-10934301-B2 | Pyrazolopyrimidine derivatives | P2RX5, RECQL, P2RX1 | MAPT 4495/4885ALDH1A1 1228/4885KDM4E 1445/4885 |
| US-20200299299-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES | P2RX5, RECQL, P2RX1 | MAPT 4346/4885ALDH1A1 1241/4885KDM4E 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.